

ORIGINAL ARTICLE

Sutureless robotic-assisted partial nephrectomy: a propensity score-matched analysis (UroCCR N.158)

Alexandre BLANCO ¹ *, Gaëlle MARGUE ^{1,2,3}, Mokrane YACCOUB ⁴,
Clément KLEIN ¹, Vincent ESTRADE ¹, Éric ALEZRA ¹, Grégoire CAPON ¹,
Franck BLADOU ¹, Grégoire ROBERT ¹, Jean-Christophe BERNHARD ^{1,2,3}

¹Department of Urology and Kidney Transplantation, CHU de Bordeaux, Bordeaux, France; ²CaRe Bordeaux – BRIC INSERM U1312, Bordeaux, France; ³French AFU Cancer Committee Guidelines, Paris, France; ⁴Department of Pathology, CHU de Bordeaux, Bordeaux, France.

*Corresponding author: Alexandre Blanco, Department of Urology and Kidney Transplantation, CHU de Bordeaux, 33076 Bordeaux, France. E-mail: alexandre.blanco@chu-bordeaux.fr

ABSTRACT

BACKGROUND: Sutureless (SL) techniques have emerged as an alternative to standard renorrhaphy (RR) in robot-assisted partial nephrectomy (RAPN), aiming to reduce the potential adverse effects of parenchymal suturing on renal function, especially in off-clamp procedures. The aim of this article is to compare perioperative, functional, and oncological outcomes of sutureless *versus* renorrhaphy-based off-clamp RAPN in a matched cohort.

METHODS: Between June 2020 and March 2024, 410 off-clamp RAPN were included in the UroCCR database. A 2:1 propensity score matching was performed based on the R.E.N.A.L. nephrometry score for comparison of SL and RR groups. The primary endpoint was trifecta achievement (negative surgical margins, no major complications (Clavien–Dindo \geq III), and preservation of \geq 90% of preoperative eGFR at first follow-up).

RESULTS: Of 410 off-clamp RAPN, 112 were sutureless and 298 with renorrhaphy. After matching, 112 SL and 224 RR cases were included. Trifecta achievement was superior in the SL group (66.1% *vs.* 43.3%, $P < 0.001$), mainly due to early renal function recovery. SL patients had reduced blood loss (103 *vs.* 344 mL, $P < 0.001$), shorter operative time (145 *vs.* 176 min, $P = 0.001$), and fewer intraoperative complications (0.9% *vs.* 5.4%, $P = 0.04$). Postoperative morbidity, long-term renal function, and oncological outcomes, including margin status, recurrence and survival, were comparable between groups.

CONCLUSIONS: In selected off-clamp RAPN cases, the omission of parenchymal and capsular renorrhaphy appears to be a safe and effective strategy that may enhance early functional outcomes and reduce operative time, without increasing perioperative morbidity or compromising oncological safety.

(Cite this article as: Blanco A, Margue G, Yacoub M, Klein C, Estrade V, Alezra É, *et al.* Sutureless robotic-assisted partial nephrectomy: a propensity score-matched analysis (UroCCR N.158). *Minerva Urol Nephrol* 2026;78:108-17. DOI: 10.23736/S2724-6051.25.06623-6)

KEY WORDS: Nephrectomy; Robotic surgical procedures; Hemostasis; Kidney neoplasms; Glomerular filtration rate.

Kidney cancer is of increasing incidence worldwide with the majority of cases diagnosed at a localized stage.¹ Partial nephrectomy (PN) is the standard of care for clinical T1 renal tumors, aiming to achieve oncological control while preserving renal function. In cases requiring vascular clamping, current guidelines recommend limiting warm ischemia time (WIT) to

under 25 minutes to minimize ischemic injury to the renal parenchyma.²

In recent years, the widespread adoption of robot-assisted partial nephrectomy (RAPN) has enabled increasingly complex nephron-sparing procedures even in anatomically challenging tumors.^{3,4} To further optimize renal functional outcomes, several ischemia-reduction strategies,

such as selective clamping, early unclamping, and off-clamp approaches, have been developed.⁵⁻⁷ Among these, off-clamp RAPN is particularly attractive as it avoids renal pedicle occlusion altogether, thereby eliminating ischemic injury. However, this technique requires meticulous hemostasis of the tumor bed in the absence of vascular control.

Traditionally, hemostasis is achieved through renorrhaphy, often involving multi-layered parenchymal and capsular sutures. However, emerging evidence suggests that renorrhaphy may contribute to renal function deterioration due to parenchymal compression, vascular ligation, or induced inflammatory response.⁸⁻¹⁰ These concerns have sparked a growing interest in sutureless techniques¹¹ that rely on meticulous excision and targeted coagulation without routine parenchymal reconstruction, particularly in the off-clamp setting.¹²⁻¹⁴ In this context, the true necessity of parenchymal suturing in off-clamp RAPN is being questioned. Sutureless techniques may offer a less traumatic alternative, with the potential to enhance early postoperative renal function without compromising perioperative safety or oncological efficacy.

This study aimed to evaluate the perioperative, functional, and oncological outcomes of sutureless off-clamp RAPN compared to conventional renorrhaphy, using a propensity score-matched analysis in a high-volume academic center.

Materials and methods

Study design and population

All consecutive patients who underwent off-clamp RAPN for a localized kidney tumor at our institution between June 2020 and March 2024 were prospectively included, and their data were recorded in the French Research Network on Kidney Cancer database, UroCCR (NCT03293563). All patients provided informed consent, and the study protocol received institutional review board approval (CNIL N. DR-2022-091) and ethical clearance from the Sud-Ouest et Outre-Mer III Ethics Committee (DC 2012/108).

Exclusions included metastatic disease, age under 18 years, and hereditary renal cancer syn-

dromes (e.g., Von Hippel–Lindau disease), to avoid bias related to multifocal or iterative tumor resections.

Surgical technique

All procedures were performed using an off-clamp technique. The kidney was mobilized and defatted, and tumor margins were delineated with or without intraoperative ultrasound. Tumor excision was performed following the enucleation plane to minimize bleeding and parenchymal trauma. Hemostasis was achieved through progressive monopolar coagulation. When required, Hem-o-lok® clips were used to control bleeding vessels exceeding the limits of thermal coagulation. Adjunctive hemostatic agents were applied as necessary. In cases involving entry into the collecting system, a selective suture was placed to close the defect. No parenchymal or capsular sutures were performed in sutureless cases.

In the renorrhaphy group, parenchymal reconstruction was performed based on surgeon preference and intraoperative findings, using capsular, parenchymal, or combined suturing techniques.

Data collection

The following variables were collected:

- demographics and clinical data: sex, age at surgery, American Society of Anesthesiologists (ASA) score, body mass index (BMI), indication for nephron-sparing surgery, and presence of multiple tumorectomies;
- tumor characteristics: tumor size, TNM classification (according to the 2017 UICC version), R.E.N.A.L. nephrometry score, malignancy status, and histological subtype were also collected;
- renal function metrics: serum creatinine and estimated glomerular filtration rate (eGFR - CKD-EPI 2021), were measured preoperatively, on postoperative at day 1, and at follow-up visits. Postoperative renal function was reassessed at the first follow-up visit, at 1-3 months.

Outcomes

The primary endpoint was the achievement of the trifecta,¹⁵ defined as the combination of negative surgical margins, absence of major complications (Clavien-Dindo grade \geq III), and preser-

vation of at least 90% of preoperative eGFR at first follow-up.

Secondary outcomes included operative time, intra and postoperative complications (assessed using the Clavien-Dindo Classification), estimated blood loss, length of hospital stay, occurrence of acute kidney injury (AKI), variation in eGFR, CKD stage progression, and oncologic endpoints (positive surgical margin, local recurrence and disease progression rates, recurrence free and overall survival). Pathological characteristics (pTNM stage and histological subtype) were also analyzed.

Postoperative follow-up was conducted according to national guidelines of the French Association of Urology(17).

Statistical analysis

Descriptive statistics were used to summarize baseline patients and tumors characteristics. Continuous variables were expressed as means and standard deviation or medians with interquartile range (IQR) and compared using the Student’s *t*-test or Mann-Whitney U Test, depending on distribution (assessed via the Shapiro-Wilk Test). Categorical variables were compared using χ^2 or Fisher’s Exact Tests, as appropriate.

To minimize selection bias, a 2:1 propensity

score matching was performed on the R.E.N.A.L. nephrometry score. Logistic regression was used for categorical outcomes and linear regression for continuous outcomes. Kaplan-Meier curves were generated for recurrence-free survival (RFS) and overall survival (OS), and differences between groups were assessed using the log-rank test. All analyses were conducted using R software version 4.4.1 (2024-06-14 ucrt) with statistical significance set at $P \leq 0.05$.

Results

Study population

Between June 2020 and March 2024, 410 consecutive patients underwent off-clamp RAPN at our center. Among them, 112 patients were treated with a sutureless (SL) technique and 298 with conventional renorrhaphy (RR). After 2:1 propensity score matching based on the R.E.N.A.L. nephrometry score, 112 SL patients were compared to 224 RR patients. The study flow chart is presented in Figure 1.

Baseline demographic and clinical characteristics were well balanced between groups following matching (Table I). There was no significant difference regarding age (60.3 ± 13.2 vs. 61.3 ± 13.9 years, $P=0.5$), sex distribution (67.9%




Figure 1.—Study flow chart. Flow diagram illustrating patient selection for inclusion in the sutureless (SL) and renorrhaphy (RR) groups. Exclusions included metastatic disease, age under 18 years, and hereditary renal cancer. A 2:1 propensity score matching based on the R.E.N.A.L. nephrometry score was then performed to obtain the final cohorts.

TABLE I.—Baseline characteristics before and after propensity score matching.

Parameter	Before matching			After matching		
	SL (N.=112)	RR (N.=298)	P value	SL (N.=112)	RR (N.=224)	P value
Age (years)	60.3±13.2	60.7±14.4	0.8	60.3±13.2	61.3±13.9	0.5
Sex						
Male	76 (67.9%)	201 (67.4%)	1	76 (67.9%)	152 (67.9%)	1
Female	36 (32.1%)	97 (32.6%)		36 (32.1%)	72 (32.1%)	
BMI (kg.m ²)	27.3±5.6	27.8±5.5	0.4	27.3±5.5	27.9±5.5	0.4
ASA score						
1	19 (17.0%)	51 (17.1%)	0.9	19 (17.0%)	36 (16.1%)	0.9
2	64 (57.1%)	168 (56.4%)		64 (57.1%)	129 (57.6%)	
≥3	29 (25.9%)	79 (26.5%)		29 (25.9%)	59 (26.3%)	
Tumor size (cm)	3.7±1.7	4.1±1.9	0.04*	3.7±1.7	3.7±1.6	0.8
cTNM						
T1a	68 (60.7%)	156 (52.3%)	0.5	68 (60.7%)	136 (60.7%)	0.9
T1b	36 (32.1%)	105 (35.2%)		36 (32.1%)	75 (33.5%)	
T2a	4 (3.6%)	19 (6.4%)		4 (3.6%)	6 (2.7%)	
T2b	2 (1.8%)	10 (3.4%)		2 (1.8%)	3 (1.3%)	
T3a	2 (1.8%)	8 (2.7%)		2 (1.8%)	4 (1.8%)	
Indication for NSS			0.7			0.5
Elective	86 (76.8%)	238 (79.9%)		86 (76.8%)	181 (80.8%)	
Imperative	15 (13.4%)	33 (11.1%)		15 (13.4%)	21 (9.4%)	
Relative	11 (9.8%)	27 (9.1%)		11 (9.8%)	22 (9.8%)	
Solitary kidney	6 (5.4%)	17 (5.7%)	1	6 (5.4%)	11 (5.4%)	0.8
Multiple tumorectomies	6 (5.4%)	24 (8.1%)	0.5	6 (5.4%)	17 (7.6%)	0.6
RENAL score	7.1±1.8	7.8±1.9	0.001*	7.1±1.8	7.3±1.8	0.3
Low complexity	43 (38.4%)	78 (26.3%)		43 (38.4%)	75 (33.5%)	
Intermediate complexity	58 (51.8%)	142 (47.9%)		58 (51.8%)	122 (54.5%)	
High complexity	11 (9.8%)	73 (24.6%)		11 (9.8%)	27 (12.1%)	
Preoperative eGFR (mL/min)	84.6±19.7	84.6±23.5	0.9	84.6±19.7	84.6±22.9	0.9
Preoperative CKD stage						
1-2	100 (90.1%)	252 (86.3%)	0.6	100 (90.1%)	190 (87.2%)	0.8
3	10 (9.0%)	36 (12.3%)		10 (9.0%)	25 (11.5%)	
4	1 (0.9%)	2 (0.7%)		1 (0.9%)	2 (0.9%)	
5	0 (0.0%)	2 (0.7%)		0 (0.0%)	1 (0.5%)	

SL: sutureless; RR: renorrhaphy, BMI: Body Mass Index; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease

*Statistically significant difference.

male in both groups), BMI (27.3±5.5 vs. 27.9±5.5 kg/m², P=0.4), ASA score, tumor size (3.7±1.6 cm in both groups, P=0.8), clinical stage (T1a in 60.7% of patients), or R.E.N.A.L score (7.1±1.8 vs. 7.3±1.8, P=0.3). Preoperative renal function was comparable with a mean eGFR of 84.6 mL/min in both groups.

Trifecta achievement

The trifecta was achieved in 66.1% of patients in the SL group versus 43.3% in the RR group (P<0.001) (Table II). This difference was primarily driven by better preservation of renal function, with 68.8% of SL patients maintain-

TABLE II.—Trifecta achievement and component criteria in SL and RR groups.

Parameter	SL (N.=112)	RR (N.=224)	P value
Trifecta achievement	74 (66.1%)	97 (43.3%)	<0.001*
Individual criteria failure			
Positive margins	2 (1.8%)	11 (4.9%)	0.1
Severe complications (Clavien–Dindo grade III–IV) within 30 days	1 (0.9%)	3 (1.3%)	0.7*
Patients with <90% preservation of preoperative eGFR at first follow-up ^a	35 (31.2%)	116 (51.8%)	<0.001*

SL: sutureless; RR: renorrhaphy; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease.

^a Mean±SD in months: SL: 2.28±1.00; RR: 2.13±1.01; *statistically significant difference.

ing $\geq 90\%$ of their preoperative eGFR at first follow-up, compared to 48.2% in the RR group ($P < 0.001$). Rates of positive surgical margins (1.8% vs. 4.9%, $P = 0.1$) and severe complications (0.9% vs. 1.3%, $P = 0.7$) were low and not significantly different between groups. In both groups, no patient failed all three trifecta criteria. Patient flow and corresponding trifecta status in both groups after matching are displayed in Figure 2.

Perioperative outcomes

Sutureless RAPN was associated with significantly reduced blood loss (103.2 ± 135.2 vs. 343.9 ± 407.9 mL, $P < 0.001$) and shorter operative time (144.6 ± 54.6 vs. 175.8 ± 60.9 minutes, $P = 0.001$) (Table III). Hemostasis was achieved using electrocoagulation alone in 35.6% of SL cases. Hemostatic agents were used in 64.4% of SL procedures vs. 31.3% in the RR group

($P < 0.001$). Intraoperative complications were less frequent in the SL group (0.9% vs. 5.4%, $P = 0.04$).

There was no significant difference in postoperative surgical complication rates between both groups (1.8% vs. 2.7%, $P = 0.4$). Medical complications occurred in 11.6% of SL patients versus 17.4% in the RR group ($P = 0.15$), with no significant difference in severe complications (0.9% vs. 1.3%, $P = 0.7$). Mean hospital stay was comparable between groups (1.2 ± 1.8 vs. 1.3 ± 1.3 days, $P = 0.5$).

Functional outcomes

At postoperative day 1, mean eGFR was higher in the SL group (67.8 ± 23.7 vs. 64.0 ± 24.9 mL/min, $P = 0.1$) and the decline from baseline was significantly lower (-16.4 ± 12.6 vs. -20.8 ± 14.6 mL/min, $P = 0.004$). Results are summarized in Table IV.




Figure 2.—Sankey diagram showing patient flow and trifecta outcomes in SL vs. RR groups after matching. Margins +: positive surgical margins; Clavien \geq III: major postoperative complications (Clavien-Dindo grade \geq III); eGFR <90%: failure to preserve $\geq 90\%$ of preoperative estimated glomerular filtration rate at first follow-up.

TABLE III.—*Perioperative and postoperative morbidity outcomes.*

Parameter	SL (N.=112)	RR (N.=224)	P value
Blood loss (mL)	103.2±135.2	343.9±407.9	<0.001*
Operative duration (min)	144.6±54.6	175.8±60.9	0.001*
Intraoperative complications	1 (0.9%)	12 (5.4%)	0.04*
Intraoperative surgical complications type			
Hemorrhagic	0 (0%)	6 (2.7%)	
Vascular injury	0 (0%)	2 (0.9%)	
Digestive tract injury	1 (0.9%)	3 (1.3%)	
Ureteral injury	0 (0%)	1 (0.4%)	
Postop surgical complications	2 (1.8%)	6 (2.7%)	0.4
Postop medical complications	13 (11.6%)	39 (17.4%)	0.15
30-day postop event complications (Clavien Dindo)			
Mild-moderate (Grade I-II)	12 (10.7%)	34 (15.2%)	0.2*
Severe (Grade III-IV)	1 (0.9%)	3 (1.3%)	0.7*
Length of hospital stay (days)	1.2±1.8	1.3±1.3	0.5

SL: sutureless; RR: renorrhaphy.

*Statistically significant difference.

TABLE IV.—*Functional outcomes over time.*

Parameters	SL (N.=112)	RR (N.=224)	P value
eGFR according to CKD-EPI formula (mL/min)			
Day 1	67.8±23.7	64.0±24.9	0.1
First follow-up ^b	83.5±22.3	79.5±23.5	0.1
Last follow-up ^c	79.7±20.8	78.0±23.1	0.07
Postoperative AKI	0 (0.0%)	3 (1.3%)	0.9
Change in eGFR compared to preop (mL/min)			
Day 1	-16.4±12.6	-20.8±14.6	0.004*
First follow-up ^b	-0.4±8.1	-5.2±9.8	<0.001*
Last follow-up ^c	-5.0±11.7	-6.9±11.2	0.07
CKD upstaging compared to preop ^a			
Day 1	60 (55.6%)	136 (61.5%)	0.21
First follow-up ^b	11 (11.8%)	33 (19.5%)	0.20
Last follow-up ^c	17 (21.8%)	30 (22.4%)	0.65

SL: sutureless; RR: renorrhaphy; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; SD: standard deviation.

^a The percentage of CKD upstaging at each follow-up time point is calculated based on the number of patients still being followed at that time; ^b mean in months SL: 2.28±1.00; RR: 2.13±1.01; ^c mean in months SL: 15.2±10.5; RR: 18.1±11.8.

At first follow-up, mean eGFR remained significantly higher in SL patients (83.5±22.3 vs. 79.5±23.5 mL/min, $P<0.001$). At last follow-up (15.2±10.5 vs. 18.1±11.8 months), this difference was no longer statistically significant (79.7±20.8 vs. 78.0±23.1, $P=0.07$).

CKD upstaging rates were similar at last follow-up (33.0% vs. 39.7%, $P=0.2$), and no acute kidney injury occurred in the SL group, compared to 1.3% in the RR group.


Oncological outcomes

Positive surgical margins were observed in 1.8% of SL patients and 4.9% of RR patients ($P=0.1$). Local recurrence occurred in three

patients (2.7%) in the SL group vs. 11 (4.9%) in the RR group ($P=0.3$). Metastatic progression was reported in one patient (0.9%) in the SL group and in nine patients (4.0%) in the RR group ($P=0.2$).

When considering both local recurrence and metastatic progression as a composite disease recurrence endpoint, the median time to recurrence was comparable between groups: 10.4 months (IQR 4.6–19.7) in the SL group vs. 9.8 months (IQR 3.1–20.6) in the RR group ($P=0.8$). The Kaplan-Meier curve for disease-free survival, based on this combined recurrence endpoint, showed no significant difference between groups ($P=0.85$) (Figure 3).

Figure 3.—Kaplan–Meier curve for disease-free survival in the SL and RR groups. Disease-free survival was defined as the time from surgery to either local recurrence or metastatic progression.



Pathological characteristics

Histological malignancy was confirmed in 84.8% of SL patients and 91.5% of RR patients (P=0.09).

Clear cell renal cell carcinoma (ccRCC) was the most common histological type in both groups, with 52.7% in SL and 64.7% in RR (P=0.10).

No statistically significant difference was observed regarding pTNM stage distribution (P=0.11).

Discussion

In this propensity score-matched cohort of patients undergoing off-clamp RAPN, the sutureless technique was associated with a significantly higher trifecta achievement rate compared to standard renorrhaphy. This difference was primarily driven by greater preservation of renal function at first follow-up, with more patients in the sutureless group maintaining $\geq 90\%$ of their baseline eGFR. These findings are aligned with growing evidence suggesting that the renorrhaphy step, historically considered essential for hemostasis and parenchymal reconstruction, may in fact contribute to functional deterioration. Proposed mechanisms include parenchymal compression, inadvertent vessel ligation, and inflammatory activation induced by mechanical stress.^{8-10, 16} This concept is supported by

the systematic review by Bertolo *et al.*,¹⁷ which demonstrated better renal function preservation with single-layer compared to double-layer renorrhaphy, reinforcing the notion that “less is more” in parenchymal reconstruction. Our study further supports this concept, showing that complete omission of parenchymal suturing can be safely achieved in selected cases when hemostasis is adequate. The omission of renorrhaphy did not result in increased intra or post-operative bleeding complications underscoring the safety and reproducibility of this approach in selected patients.

The functional benefit observed with the sutureless technique was most pronounced at early time points and appeared to attenuate over time. At final follow-up, eGFR levels and CKD stage upstaging rates were comparable between the groups. These findings are consistent with previous studies, including that of Brassetti *et al.*, which highlighted a short-term functional advantage without long-term divergence in CKD trajectories.¹⁴ Notably, our study includes a longer follow-up period (mean 15.2±10.5 months in the sutureless group and 18.1±11.8 months), which further supports that early preservation does not necessarily translate into durable functional superiority.

However, this early preservation may still carry clinical relevance, particularly in patients with borderline baseline renal function or a solitary kidney, where short-term protection could

prevent acute decompensation or facilitate subsequent treatments.

Our findings align with those of Bertolo *et al.*,^{16, 18} who reported comparable perioperative outcomes and renal function preservation between single- and double-layer renorrhaphy during robot-assisted partial nephrectomy.

In line with this, the EAU YAU pooled analysis¹⁹ found that tumor enucleation reduced complications, renal function loss, and the need for clamping, supporting the feasibility of precise off-clamp enucleation procedures and potentially sutureless approaches. All procedures in our cohort were performed using an off-clamp strategy, eliminating warm ischemia as a confounding factor and allowing for an isolated assessment of the impact of renorrhaphy. In this context, sutureless hemostasis — achieved through monopolar coagulation and hemostatic agents — appeared sufficient to control bleeding in the vast majority of cases. These results are consistent with preclinical findings demonstrating that soft coagulation induces limited, superficial thermal damage to the renal cortex,²⁰ and with clinical reports supporting the safety of this approach.^{21, 22}

The role of robotic technology in enabling such precision should also be highlighted,²³ as it has been associated with better functional outcomes and hemostatic accuracy in off-clamp procedures, indirectly supporting the feasibility of sutureless approaches.

The lower intraoperative complication rate observed in the sutureless group may reflect both the atraumatic nature of the technique and a potential selection bias. Indeed, the decision to omit parenchymal suturing was made intraoperatively based on the adequacy of hemostasis, potentially excluding more hemorrhagic or complex resections. While this pragmatic decision-making reflects real-world surgical practice, it also introduces a bias that must be acknowledged. Prospective protocols with predefined criteria for sutureless eligibility may help standardize patient selection in future studies.

This technique was developed and applied in a high-volume center by experienced robotic surgeons, which likely contributed to its reproducibility and safety across a range of tumor complexities. Nevertheless, sutureless partial

nephrectomy may represent a feasible option for surgeons willing to adopt this approach, particularly in cases with favorable anatomy or low-complexity tumors. Current EAU Guidelines report comparable safety and functional outcomes between off- and on-clamp approaches, while recommending off-clamp techniques mainly for selected patients such as those with pre-existing renal impairment or a solitary kidney.

Another relevant consideration is the inflammatory response triggered by renorrhaphy. Experimental data suggest that suturing may induce localized ischemia and chronic inflammation, which could impair microvascular integrity and nephron function over time.^{24, 25} The absence of this mechanical injury in sutureless RAPN may partially explain the observed functional benefit. Future studies integrating inflammatory biomarkers such as platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and C-reactive protein may help elucidate this mechanism further.

Our evaluation of functional outcomes was based on global eGFR, which reflects overall renal performance but does not isolate the contribution of the operated kidney. This represents a methodological limitation, as contralateral compensatory hyperfiltration may mask subtle unilateral loss. Future studies should integrate imaging-based functional assessments such as renal scintigraphy²⁶ or pre/postoperative volumetric CT analysis²⁷ to more accurately quantify parenchymal preservation.

Our findings align with those of Liu *et al.*, whose meta-analysis demonstrated that sutureless partial nephrectomy offers improved renal function preservation, shorter operative times, and comparable complication rates when compared to standard renorrhaphy.²⁸ Taken together, these results support the selective use of sutureless techniques in appropriately chosen patients.

Importantly, our data reinforce the notion that in off-clamp RAPN, the absence of parenchymal suturing, when hemostasis is adequately secured, does not compromise perioperative safety. Electrosurgical hemostasis, complemented when necessary by topical hemostatic agents, appears sufficient to manage the tumor bed in most cases. These results challenge the traditional assump-

tion that parenchymal reconstruction is always necessary and support the emergence of a new paradigm in nephron-sparing surgery: sutureless resection as a viable and potentially preferable option once hemostasis has been achieved at the end of the tumorectomy phase.

Another avenue for enhancing functional preservation in nephron-sparing surgery lies in the integration of three-dimensional (3D) preoperative planning and image guidance. Recent studies have shown that 3D modeling can significantly improve the surgeon's ability to anticipate tumor depth, vascular anatomy, and proximity to the collecting system, thereby facilitating parenchymal sparing and tailored reconstruction. In particular, 3D-assisted approaches may prove especially valuable in the context of sutureless techniques, where precise excision and selective hemostasis are critical. A multicenter propensity score–matched analysis by Michiels *et al.*²⁹ demonstrated that 3D image-guided RAPN was associated with improved functional outcomes and greater accuracy in planning elective urinary tract reconstruction. These tools may help better identify cases in which renorrhaphy can be safely omitted, and conversely, when collecting system involvement warrants selective closure. As such, the use of 3D planning could serve as a valuable adjunct to intraoperative decision-making in future sutureless surgery protocols.

Beyond clinical outcomes, this approach also carries procedural and logistical advantages. The technique is reproducible and does not require advanced suturing skills, making it accessible to centers beyond high-volume referral institutions, provided the surgical team is experienced with off-clamp nephrectomy. The absence of renorrhaphy simplifies the operative workflow and may enhance efficiency. Indeed, in our cohort, operative time was reduced by approximately 30 minutes in the sutureless group compared to standard renorrhaphy. While this difference may seem modest, it represents a 17% decrease in operative time and becomes substantial when extrapolated across high-volume programs or resource-limited settings. As emphasized by Martins *et al.*, operating room time remains a major driver of robotic surgery costs, alongside equipment and personnel.³⁰ Streamlined approaches

such as sutureless RAPN may thus contribute meaningfully to cost containment and procedural optimization.

Oncologic follow-up in our study, while adequate to detect early events, remains limited in duration. Although local recurrence and progression rates did not significantly differ between groups, longer-term prospective data are needed to fully assess oncological durability and validate these findings.

Conclusions

In this propensity score–matched study of off-clamp RAPN, the sutureless technique was associated with higher trifecta achievement, mainly due to improved early renal function preservation. Perioperative and oncological outcomes were comparable to those of standard renorrhaphy.

These results support the selective use of sutureless approaches in cases where hemostasis is adequately achieved. This technique appears to be safe, and potentially beneficial for functional outcomes and operative efficiency. Further studies are needed to validate its long-term impact and optimize patient selection.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394–424.
2. Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, Frank I, *et al.* Every minute counts when the renal hilum is clamped during partial nephrectomy. *Eur Urol* 2010;58:340–5.
3. Wu Z, Li M, Song S, Ye H, Yang Q, Liu B, *et al.* Propensity-score matched analysis comparing robot-assisted with laparoscopic partial nephrectomy. *BJU Int* 2015;115:437–45.
4. Kowalewski KF, Neuberger M, Sidoti Abate MA, Kirchner M, Haney CM, Siegel F, *et al.* Randomized Controlled Feasibility Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy: the ROBOCOP II Study. *Eur Urol Oncol* 2024;7:91–7.
5. Desai MM, de Castro Abreu AL, Leslie S, Cai J, Huang EY, Lewandowski PM, *et al.* Robotic partial nephrectomy with superselective versus main artery clamping: a retrospective comparison. *Eur Urol* 2014;66:713–9.
6. Peyronnet B, Baumert H, Mathieu R, Masson-Lecomte A, Grassano Y, Roumiguié M, *et al.* Early unclamping technique during robot-assisted laparoscopic partial nephrectomy can minimise warm ischaemia without increasing morbidity. *BJU Int* 2014;114:741–7.

7. Mellouki A, Bentellis I, Morrone A, Doumerc N, Beauval JB, Roupret M, *et al.* Evaluation of oncological outcomes of robotic partial nephrectomy according to the type of hilar control approach (On-clamp vs Off-clamp), a multicentric study of the French network of research on kidney cancer-UROCCR 58-NCT03293563. *World J Urol* 2023;41:287–94.
8. Ito H, Nakane K, Hagiwara N, Kawase M, Kato D, Iinuma K, *et al.* Impact of Robotic-Assisted Partial Nephrectomy with Single Layer versus Double Layer Renorrhaphy on Post-operative Renal Function. *Curr Oncol* 2024;31:2758–68.
9. Garofano G, Saitta C, Paciotti M, Diana P, Fasulo V, Meagher MF, *et al.* MP67-03 impact of number of inner and outer renorrhaphy stitches on functional outcomes after robotic assisted partial nephrectomy. *J Urol* 2024.
10. Shatagopam K, Bahler CD, Sundaram CP. Renorrhaphy techniques and effect on renal function with robotic partial nephrectomy. *World J Urol* 2020;38:1109–12.
11. Subirá-Ríos D, Trapero-Moreno D, Caño-Velasco J, González-García J, Moncada-Iribarren I, Aragón-Chamizo J, *et al.* A new surgical technique for sutureless partial nephrectomy: renal sutureless device. *Minerva Urol Nephrol* 2023;75:521–8.
12. Franco A, Riolo S, Tema G, Guidotti A, Brassetti A, Anceschi U, *et al.* Renal Function Preservation in Purely Off-Clamp Sutureless Robotic Partial Nephrectomy: Initial Experience and Technique. *Diagnostics (Basel)* 2024;14:1579.
13. Daou S, Albeaini S, Mjaess G, Diamand R, Albisinni S, Roumequère T, *et al.* Renorrhaphy techniques in minimally invasive partial nephrectomy: a systematic review of the literature. *Minerva Urol Nephrol* 2023;75:683–95.
14. Brassetti A, Misuraca L, Anceschi U, Bove AM, Costantini M, Ferriero MC, *et al.* Sutureless Purely Off-Clamp Robot-Assisted Partial Nephrectomy: Avoiding Renorrhaphy Does Not Jeopardize Surgical and Functional Outcomes. *Cancers (Basel)* 2023;15:698.
15. Hung AJ, Cai J, Simmons MN, Gill IS. “Trifecta” in partial nephrectomy. *J Urol* 2013;189:36–42.
16. Bertolo R, Ditonno F, Vecchia A, DE Marco V, Migliorini F, Porcaro AB, *et al.* Single-layer versus double-layer renorrhaphy technique during robot-assisted partial nephrectomy: impact on perioperative outcomes, complications, and functional outcomes. *Minerva Urol Nephrol* 2024;76:176–84.
17. Bertolo R, Campi R, Mir MC, Klatt T, Kriegmair MC, Salagierski M, *et al.*; Young Academic Urologists Kidney Cancer Working Group of the European Urological Association. Systematic Review and Pooled Analysis of the Impact of Renorrhaphy Techniques on Renal Functional Outcome After Partial Nephrectomy. *Eur Urol Oncol* 2019;2:572–5.
18. Roussel E, Amparore D, Bertolo R, Pecoraro A, Campi R, Mottrie A; European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group. “Sutureless success:” can new devices make renorrhaphy after partial nephrectomy obsolete? *Minerva Urol Nephrol* 2023;75:788–90.
19. Bertolo R, Pecoraro A, Carbonara U, Amparore D, Diana P, Muselaers S, *et al.*; European Association of Urology Young Academic Urologists Renal Cancer Working Group. Resection Techniques During Robotic Partial Nephrectomy: A Systematic Review. *Eur Urol Open Sci* 2023;52:7–21.
20. Fujisaki A, Takayama T, Teratani T, Kubo T, Kamei J, Sugihara T, *et al.* Histological and radiological evaluation of thermal denaturation depth using soft coagulation during partial nephrectomy in living pigs. *Int J Urol* 2021;28:1274–80.
21. Ota T, Komori H, Rii J, Ochi A, Suzuki K, Shiga N, *et al.* Soft coagulation in partial nephrectomy without renorrhaphy: feasibility of a new technique and early outcomes. *Int J Urol* 2014;21:244–7.
22. Yoshida T, Okinaka Y, Tomita K, Tsuru T, Kageyama S, Narita M, *et al.* Off-clamp tumor excision using soft coagulation in laparoscopic and robotic partial nephrectomy. *Asian J Endosc Surg* 2020;13:519–25.
23. Bertolo R, Bove P, Sandri M, Cindolo L, Annino F, Leonardo C, *et al.*; AGILE Group (Italian Group for Advanced Laparo-Endoscopic Surgery). Cross-analysis of two randomized controlled trials to compare pure versus robot-assisted laparoscopic approach during off-clamp partial nephrectomy. *Minerva Urol Nephrol* 2022;74:5–10.
24. Taniguchi T, Muraoka K, Nishikawa K, Ikehata Y, Setoguchi K, Oka S, *et al.* Impact of platelet-lymphocyte ratio after robot-assisted partial nephrectomy with renorrhaphy. *Sci Rep* 2024;14:30986.
25. Secin FP. Importance and limits of ischemia in renal partial surgery: experimental and clinical research. *Adv Urol* 2008;2008:102461.
26. Matsuura T, Ito A, Moriguchi M, Ikarashi D, Tamura D, Kato R, *et al.* Influence of Robot-Assisted Partial Nephrectomy on Long-Term Renal Function as Assessed Using ^{99m}Tc DTPA Renal Scintigraphy. *J Endourol* 2022;36:641–6.
27. Hori Y, Obinata D, Funakoshi D, Sakurai F, Yoshizawa T, Matsui T, *et al.* Preoperative CT volumetry of estimated residual kidney for prediction of postoperative chronic kidney disease in patients with renal cell carcinoma. *Clin Exp Nephrol* 2021;25:315–21.
28. Liu P, Li Y, Shi B, Zhang Q, Guo H. The Outcome of Sutureless in Partial Nephrectomy: A Systematic Review and Meta-Analysis. *BioMed Res Int* 2022;2022:5260131.
29. Michiels C, Khene ZE, Prudhomme T, Boulenger de Hauteclouque A, Cornelis FH, Percot M, *et al.* 3D-Image guided robotic-assisted partial nephrectomy: a multi-institutional propensity score-matched analysis (UROCCR study 51). *World J Urol* 2023;41:303–13.
30. Rodrigues Martins YM, Romanelli de Castro P, Drummond Lage AP, Alves Wainstein AJ, de Vasconcellos Santos FA. Robotic surgery costs: revealing the real villains. *Int J Med Robot* 2021;17:e2311.

Conflicts of interest

The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Authors' contributions

All authors read and approved the final version of the manuscript.

Congresses

This paper was presented as an oral communication at the French Association of Urology (AFU) Congress held in Paris in November 2023, and at the American Urological Association (AUA) Annual Meeting held in Las Vegas in May 2025.

History

Manuscript accepted: November 24, 2025. - Manuscript revised: October 30, 2025. - Manuscript received: June 17, 2025.